NCT06585384View on ClinicalTrials.gov

Safety of a Strategy Combining Etanercept Administration with Repeated Contrast Ultrasound in Patients with Alzheimer's Disease

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Alzheimer Disease
Interventions
COMBINATION_PRODUCT

etanercept and repeated contrast ultrasound

Strategy combining 9 weeks of etanercept administration (50mg/week) with 5 weeks of repeated contrast ultrasound of 2 sessions per day, 5 days per week (from the fifth week of etanercept treatment)

All Listed Sponsors
lead

Fondation Ophtalmologique Adolphe de Rothschild

NETWORK